Abstract: The present invention relates to a topical composition comprising a cannabinoid, extracellular matrix component or extracellular matrix fragment, and a pharmaceutically acceptable carrier, excipient, diluent, reagent, or combinations thereof, and use thereof in the treatment skin disorders, muscle pain, and arthritic pain.
Abstract: The present invention is based on the highly soluble and bioavailable curcuminoid compositions which can be made at a commercial scale with a simple manufacturing process. Thus, the present invention relates to oral compositions comprising a curcuminoid compound, for use in the nutraceutical, pharmaceutical, food or beverage industries and its production methods.
Abstract: The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) calciphylaxis in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating calciphylaxis in a subject with one or more of the following: diabetes, chronic kidney disease, end stage renal failure, and COPD or a subject undergoing hemodialysis and/or receiving anticoagulant therapy and/or statin therapy.
Type:
Application
Filed:
August 7, 2023
Publication date:
February 8, 2024
Inventors:
James A. Tumlin, Paul L. Darke, John M. Rudey
Abstract: Disclosed is an anti-inflammatory composition containing N-benzyl-N-methyldecan-1-amine or a derivative thereof as an active ingredient. The anti-inflammatory composition contains a compound represented by a following Chemical Formula 1 as an active ingredient. wherein in the Chemical Formula 1, R1 represents hydrogen, fluorine, an alkyl group having 1 to 5 carbon atoms, or an alkoxy group having 1 to 5 carbon atoms, each of R2 and R3 independently represents an alkyl group having 1 to 5 carbon atoms.
Type:
Application
Filed:
August 1, 2023
Publication date:
February 8, 2024
Applicants:
PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION, HaYoung Meditech Inc.
Abstract: An auto-injector device includes a pre-filled syringe including a container and a stainless steel needle adhered to the container with at least one of a urethane acrylate adhesive or a urethane methacrylate adhesive. The container is filled with at least 1 mL of a pharmaceutical composition comprising epinephrine, a buffer, and water, where the pharmaceutical composition has a pH ranging between 3 and 4. The auto-injector device also includes a firing mechanism that expels about 0.3 mL of the pharmaceutical composition from the container in less than 0.5 seconds during a single injection.
Abstract: Provided herein are methods, kits and compositions for the treatment and/or prevention of ovarian cancer through the induction of an immune response against Anti-Mullerian Hormone Receptor, Type II (AMHR2).
Type:
Application
Filed:
September 7, 2023
Publication date:
February 8, 2024
Inventors:
Vincent K. Tuohy, Suparna Mazumder, Justin M. Johnson
Abstract: Dietary supplements, nutraceutical compositions, medical foods, animal feeds, and pharmaceutical compositions for treating osteoarthritis and other osteo-articular conditions involving neuropathy and associated symptoms. A synergistic composition containing a high dose range of agmatine and acceptable salts thereof and in combination with other active ingredients having salutary effects in treating osteoarthritis and other osteo-articular conditions involving neuropathy and associated symptoms. The composition prepared with excipients and compatible carriers, including but not limited to, powders, tablets, capsules, controlled release carriers, lozenges and chewable preparations, liquid suspensions, suspensions in an edible supporting matrix or foodstuff and oral rehydration solution to facilitate consumption.
Abstract: Provided are a metformin inhalation powder aerosol for treating idiopathic pulmonary fibrosis and a preparation method thereof, including following steps: pretreating a metformin raw material to obtain fine powder, and passing the obtained fine powder through a screen with a mesh size of 100-1000 microns by an pendular granulator at a rotating speed of 200 revolutions per minute to obtain soft particle clusters; pre-spheronizing clusters at a vibration frequency of 100-300 hertz to obtain particle clusters, and then rolling the particle clusters on a granulating pan and spheronizing to obtain spherical particle clusters.
Type:
Application
Filed:
July 28, 2023
Publication date:
February 8, 2024
Inventors:
Fangyan WANG, Xiujie LIU, Zhengyang SONG, Xiawei JI, Hang ZHOU, Qingzhen ZHANG, Jie DONG, Kaiqi SHI
Abstract: The present disclosure provides methods of treating coronavirus-associated diseases in an individual comprising administering to the individual an effective amount of peramivir, cidofovir, or nevirapine and an effective amount of a second antiviral agent. Also provided are methods of treating coronavirus-associated diseases in an individual comprising administering to the individual an effective amount of nevirapine and an effective amount of valacyclovir and/or nevirapine. Also provided are formulations and methods of delivering the formulations to an individual.
Abstract: The present disclosure provides methods, kits, and compositions comprising ?-alethine and one or more immune modulators and methods to determine when they are advantageous. Particular applications include the use of ?-alethine and one or more immune modulators in the treatment of cancer.
Abstract: A dosage form of lacosamide and a pharmaceutical dosage form thereof is disclosed. The dosage form includes an extended release portion and optionally an immediate release portion. Also provided are methods of providing extended release of lacosamide and treatment of a neurological or psychiatric disease or condition.
Abstract: The present invention encompasses NHE-1 inhibitors for use in the treatment of coronavirus infections, including COVID-19, alone or in combination with one or more additional therapeutic agents.
Abstract: The present disclosure provides pharmaceutical compositions of niclosamide and a protein that may be administered via inhalation These compositions may be used in nebulized, nasal, and inhaler formats. These compositions may be used to treat one or more diseases or disorders such as a viral infection or cancer.
Type:
Application
Filed:
September 17, 2021
Publication date:
February 8, 2024
Inventors:
Hugh D.C. SMYTH, Ashlee BRUNAUGH, Zachary N. WARNKEN, Hyo-Jong SEO
Abstract: The present invention provides a screening method for searching a component inhibiting the PERK pathway and/or the ATF6 pathway, and by obtaining, by the screening method, an active ingredient inhibiting myopia progression without impairing normal growth of the eyeballs (emmetropization) in children, provides eyedrops and a composition containing the active ingredient. The problems are solved by eyedrops for inhibiting myopia progression in children containing, as an active ingredient, an inhibitor of the PERK (PKR-like endoplasmic reticulum kinase) pathway and/or the ATF6 (activating transcription factor 6) pathway. The problems are solved by a screening method for an inhibitor of myopia progression in children, including a step of contacting a candidate substance with an eye-derived cell, and a step of selecting the candidate substance using, as an index, change in a protein and/or a gene of the signal transduction system of PERK and/or ATF6.
Abstract: Embodiments of the disclosure include certain formulations for methods of treating urea cycle disorders. The methods encompass compositions that comprise benzoate and phenylbutyrate that may be at certain doses and have certain ratios of the components. The benzoate and phenylbutyrate may act synergistically in treatment of the urea cycle disorders, in particular embodiments.
Type:
Application
Filed:
October 11, 2023
Publication date:
February 8, 2024
Inventors:
Juan C. Marini, Sandesh Chakravarthy Sreenath Nagamani
Abstract: The present invention provides compositions and methods for promoting glycogen synthase activity and augmenting glycogen storage capability in muscle tissue and/or liver tissue in a mammal, relating to administration to the mammal of an effective amount of p-a minoisobutyric acid (BAIBA), an analog or derivative thereof, or a pharmaceutically acceptable salt, ester, acid, polymer, analog or derivative thereof.
Abstract: This disclosure provides pharmaceutical compositions comprising amino acid entities and uses thereof. Methods for improving liver function and for treating liver diseases comprising administering an effective amount of the compositions to a subject in need thereof are also disclosed.
Type:
Application
Filed:
March 8, 2023
Publication date:
February 8, 2024
Inventors:
Michael Hamill, Raffi Afeyan, Chung-Wei Lee, Harry Luithardt
Abstract: Compositions and methods are related to utilizing glycine and N-acetylcysteine for a variety of medical conditions related to reduced levels of glycine, N-acetylcysteine, and/or glutathione, for example, muscle loss such as sarcopenia, HIV infection and other infections, organ damage such as those from diabetes and insulin resistance and diabetic nephropathy, cardiac function and failure such as preventing or improving heart failure, fatty liver, cancer prevention, and other conditions.
Type:
Application
Filed:
August 18, 2023
Publication date:
February 8, 2024
Inventors:
Stephen Kirnon, Eric Freedland, Rajagopal V. Sekhar
Abstract: This disclosure is directed is directed to compositions and methods for preventing, treating, or ameliorating the symptoms of a viral infection.
Abstract: The present disclosure provides use of a reagent for detecting retinol metabolites in preparation of a tool for diagnosing and/or treating pneumoconiosis, and relates to the technical field of biomedicine. The present disclosure verifies that retinol metabolism disturbance and all-trans retinoic acid (ATRA) deficiency are closely related to the pathogenesis of pneumoconiosis. Therefore, the present disclosure sets forth use of retinol and ATRA as biomarkers for screening the pneumoconiosis and use thereof in preparation of products related to the diagnosis of the pneumoconiosis; meanwhile, intervention of the pneumoconiosis with the ATRA can effectively delay the progression of the pneumoconiosis. Therefore, the present disclosure first sets forth use of the ATRA as a medicament for treating the pneumoconiosis.
Type:
Application
Filed:
January 19, 2023
Publication date:
February 8, 2024
Applicant:
Institute of Basic Medical Sciences of Chinese Academy of Medical Sciences
Abstract: The present invention is directed to compositions comprising N-Acetyl Methyl GABA, methods of preparing N-Acetyl Methyl GABA and compositions including N-Acetyl Methyl GABA, and methods of using N-Acetyl Methyl GABA for instance to improve sleep and control anxiety.
Abstract: Methods of administering ferric citrate to reduce and/or control serum phosphorus levels, increase serum bicarbonate levels, improve one or more iron storage parameters (e.g., increase serum ferritin levels, increase transferrin saturation (TSAT), increase hemoglobin concentration) increase iron absorption, maintain iron stores, treat iron deficiency, treat anemia, reduce the need for IV iron and/or reduce the need for erythropoiesis-stimulating agents (ESAs) in chronic kidney disease patients, are disclosed.
Type:
Application
Filed:
December 28, 2022
Publication date:
February 8, 2024
Inventors:
Enrique Poradosu, James F. Oliviero, III, Ron Bentsur
Abstract: The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.
Abstract: A2-73 is a useful therapeutic in the treatment of humans suffering from insomnia, anxiety or agitation. Particular attention is made to oral daily doses of from about 10 mg to about 50 mg, with particular reference to about 20 to 30 mg.
Abstract: Embodiments include animal feed preparation systems and methods. In an embodiment, a method of administering fine particulates with a total mixed ration includes adding total mixed ration components to a vessel. The method further includes adding the fine particulates and an aqueous composition to the vessel. The method further includes mixing the aqueous composition, the fine particulates, and the total mixed ration together to form an agglomerated total mixed ration. The method further includes providing the agglomerated total mixed ration to an animal. Other embodiments are also included herein.
Type:
Application
Filed:
July 28, 2023
Publication date:
February 8, 2024
Inventors:
Clayton V. McNeff, Larry C. McNeff, Peter G. Greuel, Emily Miller
Abstract: A senotherapeutic compound including a synthetic derivative of flavones, according to the formula (I) as indicated below: in which at least two of R2-R8 are H, and the remainder are individually selected from: H, OH, R1, OR1, NO2, NH2, NHR1, F, Cl, Br, I, where R1 is a radical.
Type:
Application
Filed:
November 30, 2021
Publication date:
February 8, 2024
Inventors:
Mario CORREALE, Giovanni GAMBERA, Giovanni Mario PITARI, Venera RUSSO
Abstract: The present invention relates to an active ingredient and a drug or composition, respectively, for use in reducing pathogenic germs in the human intestine or for use in reducing colonization of the human intestine with pathogenic germs, preferentially for the purpose of preventing, reducing or curing inflammatory diseases or preferentially for the purpose of prophylactic or therapeutic treatment of inflammatory diseases of the human body.
Type:
Application
Filed:
October 1, 2021
Publication date:
February 8, 2024
Inventors:
Michael PLOCH, Ralph PRIES, Karl-Ludwig BRUCHHAGE
Abstract: The invention provides a water-soluble composition comprising cannabis extract. The invention also provides methods of producing a water-soluble composition comprising cannabis extract. The invention further provides a solution comprising cannabis extract. Furthermore, the invention provides a frozen composition, a medication, a pharmaceutical composition, and a kit comprising a water-soluble composition comprising cannabis extract.
Type:
Application
Filed:
October 12, 2023
Publication date:
February 8, 2024
Inventors:
Hillary Peckham, Mykola Ianchenko, Joseph Stevens, Keeley Peckham
Abstract: A method of treating a microbial infection in a subject comprises administering to a subject in need thereof an effective amount of a composition comprising mycolactone (MLN). A method of preventing a microbial infection in a subject comprises administering to a subject in need thereof an effective amount of a composition comprising mycolactone (MLN).
Type:
Application
Filed:
June 30, 2023
Publication date:
February 8, 2024
Inventors:
MICHAEL DAVID WILSON, SAMUEL KOJO KWOFIE, SETH OSEI ASIEDU, PRAKASHA KEMPAIAH, YASH GUPTA, RAVINDRA V. DURVASULA
Abstract: A topical ophthalmic anesthetic composition includes a formulation with an amount of articaine to provide anesthetic properties when applied topically to the eye, and a pH, viscosity, osmolality, dissociation constant, and additives such as antioxidants, buffers, methylcellulose, to achieve efficacy and safety. The composition can contain articaine in amounts of about 4.0% w/v to about 12.0% w/v and have a pH of about pH 3.5 to pH 7.0. The buffer can be borate/mannitol complex obtained from boric acid or salt thereof and D-mannitol. The articaine formulations can achieve adequate anesthesia of the internal aspect of the eye wall by topical application, without the use of an injectable anesthetic. Exemplary implementations of the disclosure include formulations include articaine in an amount of at least 7.0% w/v, where the formulation is an aqueous solution, a gel, an ointment, or in an encapsulated form.
Abstract: The present invention relates to a pharmaceutical preparation comprising saroglitazar and myristic acid, or a salt or solvate thereof, for use in the treatment of focal segmental glomerulosclerosis (FSGS).
Abstract: The human body's response to excessive gut bacterial growth is to deny the microbiome of two classes of amino acids. This halts exponential growth; however, the body is also denied their benefit. In the short term, prevention of explosive infection is accomplished. However, this triggers the necessity of removing the needed amino acids from bodily structure for the body to continue. This becomes the resulting long-term decline seen in human aging. This disclosure is methods to extend to the body the benefit of those missing classes of amino acids by providing them in a form less accessible to bacteria. The preferred embodiments claimed in this disclosure work in tandem to treat and to slow aging.
Abstract: The disclosure provides carbazole derivatives in combination with Collagenase Clostridium histolyticum (CCH), and use thereof for the treatment of fat related conditions.
Type:
Application
Filed:
September 15, 2021
Publication date:
February 8, 2024
Inventors:
Alon BLOOMENFELD, Racheli GUETA, Eran BLAUGRUND
Abstract: Disclosed herein are compositions, kits, and methods employing combinations of (a) one or more Nrf2 agonists; and (b) one or more 3CLpro inhibitors, one or more protease inhibitors, and/or one or more N4-hydroxycytidine nucleoside to treat, inhibit, and/or reduce infections and symptoms caused by infection by a virus such as viruses belonging to the Coronaviridae family (e.g., coronaviruses), Orthomyxoviridae family, the Picornaviridae family, and the Pneumoviridae family of viruses.
Abstract: The present invention is directed to compositions comprising a Tryptophol derivative, a 4-Ethyl-Phenol derivative, or a combination thereof, and methods of using same, such as for modulating abundance, diversity, or both, of a microbial population tin a subject in need thereof.
Abstract: A method of treating cancer, where the biomarkers are predictive of response to PD-1/PD-L1 blockade and GSK-3 inhibition, and which can be used in the method of treatment.
Type:
Application
Filed:
August 4, 2023
Publication date:
February 8, 2024
Inventors:
Wafik S. EL-DEIRY, Kelsey E. HUNTINGTON, Benedito A. CARNEIRO
Abstract: The present invention concerns compounds and their use to treat cardiovascular disease, renal disease, thrombic disease, stroke, metabolic syndrome, cell proliferation, and ischemic cardiovascular disorders. Compounds of the present invention display significant potency as antagonists of 20-hydroxyeicosatetraenoic acid (20-HETE), and function as anti-hypertensive, anti-inflammatory, or anti-growth agents.
Type:
Application
Filed:
May 9, 2023
Publication date:
February 8, 2024
Inventors:
John R. Falck, Michal L. Schwartzman, Victor Garcia
Abstract: Described herein are compositions and methods for the topical administration of various compounds to the eye, in particular to the posterior portion of the eye. Such compositions and methods are useful for treating various disease and disorders, as well as in promoting the general health of the eye.
Type:
Application
Filed:
March 17, 2022
Publication date:
February 8, 2024
Inventors:
Weizhen WANG, David F. WOODWARD, Nonna SNIDER
Abstract: The present invention relates to pharmaceutical products and in particular to pharmaceutical combination products. The invention further relates to uses of such products in medical treatment. Embodiments of the invention have been particularly developed as pharmaceutical combination products of a protoparvovirus and an antiviral benzimidazole derivative or a pharmaceutically acceptable salt or prodrug of the benzimidazole derivative for use in the treatment of cancer and will be described hereinafter with reference to this application. However, it will be appreciated that the invention is not limited to this particular field of use.
Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.
Type:
Application
Filed:
October 10, 2023
Publication date:
February 8, 2024
Inventors:
Nicola Frances BATEMAN, Paul Richard GELLERT, Kathryn Jane HILL
Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.
Type:
Application
Filed:
October 10, 2023
Publication date:
February 8, 2024
Inventors:
Nicola Frances BATEMAN, Paul Richard GELLERT, Kathryn Jane HILL
Abstract: The present invention relates to a pharmaceutical composition for preventing or treating inflammatory bowel disease acting as a functional antagonist for S1PR1 and S1PR4 of S1P receptors, and more specifically, to a pharmaceutical composition including, as an active ingredient, a sphingolipid compound which does not cause cardiovascular side effects by acting as a functional antagonist for S1PR1 and S1PR4 and has an effect of preventing or treating inflammatory bowel disease.
Type:
Application
Filed:
September 28, 2023
Publication date:
February 8, 2024
Applicant:
NEXTGEN BIOSCIENCE CO., LTD.
Inventors:
Bong Yong LEE, Yang Hae PARK, Eun Jeong KIM
Abstract: The invention disclosed herein is directed to compounds of Formula I and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a selective PPAR? antagonist.
Type:
Application
Filed:
April 21, 2023
Publication date:
February 8, 2024
Inventors:
Nicholas Simon STOCK, Austin Chih-Yu CHEN, Yalda Mostofi BRAVO, Jason Duarte JACINTHO, Jill Melissa BACCEI, Brian Andrew STEARNS, Ryan Christopher CLARK
Abstract: Compositions and methods for the treatment of a human subject in need of treatment for a neutrophil-related condition, in particular who has had a stroke or myocardial ischemia reperfusion injury, by administering to the subject a pharmaceutical composition including a compound of Formula 1, wherein the substituents are as described herein, and in particular wherein the compound is 4,4-dimethyl-1-(3-nitrophenyl)-2-(1H-1,2,4-triazol-1-yl)-1-penten-3-one.
Abstract: Thromboxane A2 receptor antagonists, such as ifetroban, inhibit solid tumor metastasis. The formation of surface and microscopic lung metastases are inhibited. Thromboxane A2 receptor antagonists can inhibit the tumor metastasis process without affecting the growth or development of a primary tumor.
Abstract: Disclosed herein are methods of treating moderate to severe asthma of the eosinophilic phenotype in a human subject in need thereof with a daily dose of about 75 mg to about 300 mg of dexpramipexole or pharmaceutical acceptable salt thereof, and treating severe asthma of the eosinophilic phenotype in a human subject in need thereof with a daily dose of about 150 mg to about 300 mg of dexpramipexole or pharmaceutical acceptable salt thereof.
Abstract: Disclosed herein are methods of treating moderate to severe asthma of the eosinophilic phenotype in a human subject in need thereof with a daily dose of about 75 mg to about 300 mg of dexpramipexole or pharmaceutical acceptable salt thereof, and treating severe asthma of the eosinophilic phenotype in a human subject in need thereof with a daily dose of about 150 mg to about 300 mg of dexpramipexole or pharmaceutical acceptable salt thereof.